Biological and clinical advantages compared to tissue analysis.
Enhanced digital PCR using Beads, Emulsions, Amplification, & Magnetics
Highly sensitive and specific targeted NGS using unique molecular identifiers and additional optimizations.
The importance of high sensitivity for robust concordance with tissue
Ushering in the "plasma first" testing paradigm
Detection of ultra-low frequency mutations for ER+/HER2- disease
The OncoBEAM advantage for established therapeutic indications
Expanded RAS testing for liquid biopsy - beyond KRAS codon 12
Detecting PIK3CA and TP53 in circulating cell-free DNA for a potential early breast cancer diagnostic.
Information in accordance with Art. 13 GDPR: https://www.sysmex-inostics.com/data
Germany: Sysmex Inostics GmbH, Falkenried 88, D-20251 Hamburg, Germany. +49 40- 325907-0
United States: Sysmex Inostics, Inc., 1812 Ashland Ave Suite 500, Baltimore, Maryland 21205, USA. +1-855-BEAM-DNA (232-6362)
Japan: Sysmex Corporation, 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan. +81 78 265-0500